vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and DiamondRock Hospitality Co (DRH). Click either name above to swap in a different company.
DiamondRock Hospitality Co is the larger business by last-quarter revenue ($258.2M vs $183.1M, roughly 1.4× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 5.6%, a 7.7% gap on every dollar of revenue. On growth, DiamondRock Hospitality Co posted the faster year-over-year revenue change (1.3% vs -1.8%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -8.6%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
DiamondRock Hospitality Co is a US-based real estate investment trust owning and operating a portfolio of premium upscale hotels and resorts. Its properties are mainly located in major urban tourist and business hubs nationwide, catering to both leisure and corporate clientele seeking high-quality accommodation services.
AMPH vs DRH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $258.2M |
| Net Profit | $24.4M | $14.5M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 11.1% |
| Net Margin | 13.3% | 5.6% |
| Revenue YoY | -1.8% | 1.3% |
| Net Profit YoY | -35.7% | 22.0% |
| EPS (diluted) | $0.51 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $258.2M | ||
| Q4 25 | $183.1M | $274.5M | ||
| Q3 25 | $191.8M | $285.4M | ||
| Q2 25 | $174.4M | $305.7M | ||
| Q1 25 | $170.5M | $254.9M | ||
| Q4 24 | $186.5M | $279.1M | ||
| Q3 24 | $191.2M | $285.1M | ||
| Q2 24 | $182.4M | $309.3M |
| Q1 26 | — | $14.5M | ||
| Q4 25 | $24.4M | $26.2M | ||
| Q3 25 | $17.4M | $22.5M | ||
| Q2 25 | $31.0M | $40.8M | ||
| Q1 25 | $25.3M | $11.9M | ||
| Q4 24 | $38.0M | $-11.2M | ||
| Q3 24 | $40.4M | $26.4M | ||
| Q2 24 | $37.9M | $24.5M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | 11.1% | ||
| Q4 25 | 19.4% | 8.9% | ||
| Q3 25 | 13.2% | 8.1% | ||
| Q2 25 | 24.2% | 13.7% | ||
| Q1 25 | 21.9% | 4.3% | ||
| Q4 24 | 24.2% | -3.7% | ||
| Q3 24 | 29.8% | 9.5% | ||
| Q2 24 | 30.3% | 8.4% |
| Q1 26 | — | 5.6% | ||
| Q4 25 | 13.3% | 9.5% | ||
| Q3 25 | 9.0% | 7.9% | ||
| Q2 25 | 17.8% | 13.4% | ||
| Q1 25 | 14.8% | 4.7% | ||
| Q4 24 | 20.4% | -4.0% | ||
| Q3 24 | 21.1% | 9.3% | ||
| Q2 24 | 20.8% | 7.9% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.51 | $0.12 | ||
| Q3 25 | $0.37 | $0.10 | ||
| Q2 25 | $0.64 | $0.18 | ||
| Q1 25 | $0.51 | $0.04 | ||
| Q4 24 | $0.74 | $-0.06 | ||
| Q3 24 | $0.78 | $0.11 | ||
| Q2 24 | $0.73 | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $39.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.4B |
| Total Assets | $1.6B | $3.0B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.3M | ||
| Q4 25 | $282.8M | $68.1M | ||
| Q3 25 | $276.2M | $145.3M | ||
| Q2 25 | $231.8M | $52.4M | ||
| Q1 25 | $236.9M | $100.6M | ||
| Q4 24 | $221.6M | $81.4M | ||
| Q3 24 | $250.5M | $75.3M | ||
| Q2 24 | $217.8M | $125.2M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $1.1B | ||
| Q3 25 | $608.6M | $1.1B | ||
| Q2 25 | $607.7M | $1.0B | ||
| Q1 25 | $603.9M | $1.1B | ||
| Q4 24 | $601.6M | $1.1B | ||
| Q3 24 | $596.4M | $1.1B | ||
| Q2 24 | $586.9M | $1.2B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $788.8M | $1.4B | ||
| Q3 25 | $776.7M | $1.6B | ||
| Q2 25 | $757.5M | $1.6B | ||
| Q1 25 | $751.3M | $1.6B | ||
| Q4 24 | $732.3M | $1.6B | ||
| Q3 24 | $727.7M | $1.6B | ||
| Q2 24 | $713.3M | $1.6B |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $1.6B | $3.0B | ||
| Q3 25 | $1.7B | $3.1B | ||
| Q2 25 | $1.6B | $3.1B | ||
| Q1 25 | $1.6B | $3.1B | ||
| Q4 24 | $1.6B | $3.2B | ||
| Q3 24 | $1.5B | $3.2B | ||
| Q2 24 | $1.5B | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 0.76× | ||
| Q3 25 | 0.78× | 0.70× | ||
| Q2 25 | 0.80× | 0.65× | ||
| Q1 25 | 0.80× | 0.70× | ||
| Q4 24 | 0.82× | 0.69× | ||
| Q3 24 | 0.82× | 0.67× | ||
| Q2 24 | 0.82× | 0.71× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $67.9M | ||
| Q3 25 | $52.6M | $74.6M | ||
| Q2 25 | $35.6M | $73.6M | ||
| Q1 25 | $35.1M | $27.6M | ||
| Q4 24 | $29.0M | $75.8M | ||
| Q3 24 | $60.0M | $61.7M | ||
| Q2 24 | $69.1M | $55.7M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $47.3M | ||
| Q3 25 | $47.2M | $54.9M | ||
| Q2 25 | $25.0M | $57.9M | ||
| Q1 25 | $24.4M | $2.0M | ||
| Q4 24 | $16.6M | $52.6M | ||
| Q3 24 | $46.2M | $39.0M | ||
| Q2 24 | $63.1M | $38.8M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 17.2% | ||
| Q3 25 | 24.6% | 19.2% | ||
| Q2 25 | 14.3% | 18.9% | ||
| Q1 25 | 14.3% | 0.8% | ||
| Q4 24 | 8.9% | 18.9% | ||
| Q3 24 | 24.1% | 13.7% | ||
| Q2 24 | 34.6% | 12.5% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 7.5% | ||
| Q3 25 | 2.8% | 6.9% | ||
| Q2 25 | 6.1% | 5.1% | ||
| Q1 25 | 6.3% | 10.0% | ||
| Q4 24 | 6.7% | 8.3% | ||
| Q3 24 | 7.2% | 7.9% | ||
| Q2 24 | 3.3% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 2.59× | ||
| Q3 25 | 3.03× | 3.31× | ||
| Q2 25 | 1.15× | 1.80× | ||
| Q1 25 | 1.39× | 2.33× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 2.33× | ||
| Q2 24 | 1.82× | 2.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
DRH
| Rooms | $164.1M | 64% |
| Food and beverage | $67.2M | 26% |
| Other | $26.9M | 10% |
